GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market …
WEB2 days ago · According to TipRanks, Parry is a 3-star analyst with an average return of 3.0% and a 61.29% success rate. Parry covers the Healthcare sector, focusing on stocks such as Sanofi, GlaxoSmithKline ...
GSK shares fall after sales of top two vaccines disappoint
WEBJul 31, 2024 · Analysts at Jefferies cited weak U.S. demand, destocking and lower benefits than expected from supplies to Zhifei China after a $3 billion deal last year.
GlaxoSmithKline: Business Model, SWOT Analysis, and
WEBMar 29, 2024 · GlaxoSmithKline faces competition from other pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and Merck. A SWOT analysis reveals the company's strengths, weaknesses, opportunities, and threats in the market.
Analyst Issues Sell Rating for GlaxoSmithKline Amid Market …
WEBSep 13, 2024 · Graham Parry has given his Sell rating due to a combination of factors including concerns over GlaxoSmithKline’s commercial strategy and potential overestimation of future sales.
GSK - Statistics & Facts | Statista
WEBMar 21, 2024 · GSK - Statistics & Facts. GSK – formerly known as GlaxoSmithKline – is among the top 10 global drug manufacturers based on prescription drug sales. It is headquartered in London, and thus,...
Why GSK will struggle to mount AstraZeneca-style revival
WEBApr 23, 2021 · Next week’s first quarter numbers are expected to be weak: Covid has disrupted the rollout of vaccinations against other illnesses. But that should mean pent-up demand for Shingrix, GSK’s...
GlaxoSmithKline's Demerger Plan Has Failed To Excite Investors
WEBJul 26, 2021 · It reckons that the recent share price weakness and a recent broker-conducted survey of investors show that the group has deep credibility challenges.
GlaxoSmithKline: 30% Undervalued And Spinoff To Drive Growth
WEBJan 25, 2021 · GSK is undervalued by 52% and 44% based on P/S and P/ Cash flow respectively. In addition, GSK's 10-year median P/E is ~18x so we expect that the stock price will benefit from multiple...
Sell Rating on GSK Amidst ACIP’s Narrowed RSV ... - Markets Insider
WEBJun 26, 2024 · GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst James Gordon from J.P. Morgan maintained a Sell rating on the stock and...
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You ... - Nasdaq
WEBJan 28, 2022 · In the latest trading session, GlaxoSmithKline (GSK) closed at $45.25, marking a -1.07% move from the previous day. This change lagged the S&P 500's daily gain of 2.44%.
Skip to content